Here's What Makes Corcept Therapeutics (CORT) an Attractive Investment?

ClearBridge Investments, an investment management company, released its “Clearbridge Global Value Improvers Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global equity markets reported positive returns in Q2, driven by U.S. trade deals and expected fiscal stimulus in Europe, which countered tariff challenges and geopolitical tensions. Strong contributions from industrials and IT holdings led the strategy to outperform the benchmark MSCI World Value Index in the quarter. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its second-quarter 2025 investor letter, Clearbridge Global Value Improvers Strategy highlighted stocks such as Corcept Therapeutics Incorporated (NASDAQ:CORT). Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biotechnology company that engages in the discovery and development of medications for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders. The one-month return of Corcept Therapeutics Incorporated (NASDAQ:CORT) was 23.24%, and its shares gained 88.16% of their value over the last 52 weeks. On October 2, 2025, Corcept Therapeutics Incorporated (NASDAQ:CORT) stock closed at $85.48 per share, with a market capitalization of $9.01 billion.

Clearbridge Global Value Improvers Strategy stated the following regarding Corcept Therapeutics Incorporated (NASDAQ:CORT) in its second quarter 2025 investor letter:

"Portfolio activity was relatively calm in the quarter with only two changes: exiting Uber Technologies and adding Corcept Therapeutics Incorporated (NASDAQ:CORT). We bought Corcept, a biotech company specializing in the management of cortisol levels that now appear to have wider implications across endocrinologic, oncologic, metabolic and neurological disorders than previously understood. With a successful and profitable drug already in the market, we believe that the ongoing development and rollout of its improved product will further expand the treatment’s potential and solidify Corcept’s competitive moat."

Corcept Therapeutics Incorporated (NASDAQ:CORT) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 35 hedge fund portfolios held Corcept Therapeutics Incorporated (NASDAQ:CORT) at the end of the second quarter, up from 33 in the previous quarter. Corcept Therapeutics Incorporated (NASDAQ:CORT) reported revenue of $194.4 million in Q2 2025, compared to $163.8 million in Q2 2024. While we acknowledge the potential of Corcept Therapeutics Incorporated (NASDAQ:CORT) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Corcept Therapeutics Incorporated (NASDAQ:CORT) and shared the list of stocks with consistent growth to invest in. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.